Clinical Trial Update: Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating bi-weekly temozolomide plus bevacizumab in adults with recurrent glioblastoma multiforme and recurrent gliosarcoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme
• Gliosarcoma

Drugs mentioned

• Avastin (bevacizumab)
• Temodar (Temozolomide)

Snippet

Sponsor: Center for Neurosciences, Tucson | Conditions: Recurrent Glioblastoma Multiforme, Recurrent Gliosarcoma | Phase 2 | Status: COMPLETED